Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
PALISADE BIO INC (PALI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.16-7.20%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PALI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Strengthen Board and governance with new director appointments | New board members strengthen governance. | Intact | failure to enhance board governance by end of 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder. The long-term thesis is in a watch state: management is progressing PALI-2108, but recent financial performance is weak and the business is loss-making.
The valuation model indicates PALI is expensive versus peers, with low confidence in that estimate. The premium appears tied to the potential value of its development programs, while the evidence does not suggest the broader combination of expensive valuation, weak fundamentals, and turbulence is fully reflected in the fragility assessment.
Near term, results may remain uneven: recent earnings were in line, but financial performance is weak relative to the industry and the next-print miss risk is flagged for monitoring. Over the multi-year view, management has advanced PALI-2108 into Phase 2 and says current cash can fund operations through key clinical milestones, though cash declined modestly from the first to the second quarter of 2026.
The central swing factor is whether the planned Phase 2 ASCENTRA-UC trial starts in the second half of 2026 and progresses toward the anticipated 2027 efficacy readout. The thesis also depends on cash remaining sufficient for those milestones; a guidance cut would be a negative signal, while stronger results and guidance from healthcare bellwethers could support sector momentum.
Over the next 1 to 3 years, PALI's long-term thesis is chiefly a test of clinical execution and funding, set against weak current financial performance and high risk. The evidence supports monitoring milestones rather than treating the thesis as established. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Management is focused on controlling operating expenses despite no revenue. |
| Intact |
| operating loss exceeds $11 million per quarter persistently |
Operating income: $-11.698M FY2026-Q2; GAAP. Published target: operating loss not exceeding $11 million per quarter. Target period is not explicitly aligned with this observation. Aug 10, 2026-11,698,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Advance Phase 2 study enrollment for PALI-2108 in Ulcerative Colitis | Palisade Bio is advancing its Phase 2 trial for PALI-2108 in ulcerative colitis. | Improving | enrollment delays or failure to advance Phase 2 study within 12 months | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.28 → $-0.28 · observed estimates
$0.05B → $0.05B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.28 | $47,712,000 | 6 / 7 |
| 2026-07-25 | $-0.28 | $47,712,000 | 6 / 7 |
| 2026-07-26 | $-0.28 | $47,712,000 | 6 / 7 |
| 2026-07-27 | $-0.29 | $0 | 7 / 7 |
| 2026-07-28 | $-0.29 | $0 | 7 / 7 |
| 2026-07-29 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-07-30 | $-0.29 | $0 | 7 / 7 |
| 2026-07-31 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-01 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-02 | $-0.29 | $0 | 7 / 7 |
| 2026-08-03 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-04 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-05 | $-0.29 | $0 | 7 / 7 |
| 2026-08-06 | $-0.29 | $0 | 7 / 7 |
| 2026-08-07 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-08 | $-0.29 | $0 | 7 / 7 |
| 2026-08-09 | $-0.29 | $0 | 7 / 7 |
| 2026-08-10 | $-0.29 | $0 | 7 / 7 |
| 2026-08-12 | $-0.27 | $0 | 7 / 6 |
| 2026-08-13 | $-0.27 | $0 | 7 / 6 |
| 2026-08-14 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-15 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-16 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-17 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-18 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-19 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-20 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-21 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-22 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-23 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-24 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-25 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-26 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-27 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-28 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-29 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-30 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-08-31 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-01 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-02 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-03 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-04 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-05 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-06 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-07 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-08 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-09 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-10 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-11 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-12 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-13 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-14 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-15 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-16 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-17 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-18 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-19 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-20 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-21 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-22 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-23 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-24 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-25 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-26 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-27 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-28 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-29 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-09-30 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-10-01 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-10-02 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-10-03 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-10-04 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-10-05 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-10-06 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-10-07 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-10-08 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-10-09 | $-0.28 | $47,712,000 | 7 / 7 |
| 2026-10-10 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-11 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-12 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-13 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-14 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-15 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-16 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-17 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-18 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-19 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-20 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-21 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-22 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-23 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-24 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-25 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-26 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-27 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-28 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-29 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-30 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-10-31 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-11-01 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-11-02 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-11-03 | $-0.28 | $47,712,000 | 8 / 8 |
| 2026-11-04 | $-0.28 | $47,712,000 | 8 / 8 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 10 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.